Developer docs
API playgroundTry for free, no card

Search company profiles

LifeBond

Full company profile

uuid000g2tv

Namestring
LifeBond
Websiteurl
life-bond.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

LifeBond is a privately held medical device company founded in 2007 and headquartered in Caesarea, Israel. The company develops and manufactures biosurgical medical devices for tissue repair, operating in the regulated biomaterials segment of the surgical device market. LifeBond was incubated by Trendlines Group in 2007 and has since raised approximately $56.5 million across multiple venture rounds through August 2015, with investors including Pitango VC, Giza Venture Capital, GlenRock Israel, The Zitelman Group, BizTEC, Aurum Ventures MKI, and the strategic investor Sino Biopharmaceutical.

The company's product portfolio and underlying technology are not detailed in the source data, but its positioning as a biosurgical tissue-repair specialist implies proprietary biomaterial formulations, likely with associated patents and regulatory pathways (FDA / CE Mark) typical of the category. Founder Ishay Attar remains associated with the company, indicating continuity of technical leadership. The current organization is small, with 1–10 employees reported in the firmographic record.

LifeBond's business model is consistent with a clinical-stage or early-commercial medical device company: revenue is generated (or intended to be generated) through sales of regulated surgical products to hospitals and surgical centers, typically via specialty distributors. However, the source data does not disclose pricing, customer counts, distribution arrangements, or revenue figures, and no commercial sales milestones, product launches, or partnership announcements are documented beyond the venture financings. As a result, the company's current commercial stage cannot be confirmed from available information.

Short descriptiontext

LifeBond is an Israel-based medical device company developing and manufacturing biosurgical products for tissue repair. Founded in 2007 in Caesarea and backed by Israeli and Asian life-sciences investors, it operates as a small private venture-backed biomaterials specialist.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCaesarea, Israel
HQ citystring
Caesarea
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
biosurgical medical devices, tissue repair products, surgical hemostats, sealant medical devices, biomaterial implants
Industry2 codes
1Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates)
CodeIMAEAOALPrimaryYes
2Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
CodeHLAAAGABPrimaryNo
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Adhesives & Sealants2891
Product category
Surgical Medical Devices
Social media profiles2 records
Cost components5 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LifeBond develops and manufactures biosurgical medical devices intended for tissue repair applications. The company produces surgical sealants, hemostats, and other biomaterial-based products that surgeons use to control bleeding, seal tissues, and support healing during surgical procedures.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Biosurgical Tissue Repair Devices
CategoryBiosurgical Medical Devices
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Artivion (formerly CryoLife)
TypeDirect peer
Description

Specialized surgical adhesives and sealants (BioGlue, BioFoam) used in cardiac and vascular surgery. Directly comparable as a focused biosurgical tissue-repair and sealant company with overlapping clinical use cases.

2Ethicon (Johnson & Johnson MedTech)
TypeBroad incumbent
Description

J&J's surgical solutions arm and a global incumbent in wound closure and biosurgical adjuncts (Evicel, Omnex). Comparable as a dominant surgical sealants manufacturer with deep hospital relationships and broad portfolio reach.

3HyperBranch Medical Technology (Stryker)
TypeDirect peer
Description

Developer of Adherus surgical sealants, now part of Stryker. Comparable as a specialty biosurgical sealant developer focused on dural sealing and similar neurosurgical / ENT applications with overlapping technology profile.

4B. Braun
TypeOthers
Description

Global medical device and pharmaceutical company offering Histoacryl tissue adhesives and broader surgical sealants portfolio. Comparable as a manufacturer of cyanoacrylate-based and other surgical tissue-repair products distributed globally.

5Baxter International
TypeBroad incumbent
Description

Diversified medical products leader whose surgical sealants and hemostats (Tisseel, Floseal) are the global category standard. Directly comparable as a manufacturer of fibrin- and gelatin-based biosurgical tissue-repair products sold into the same surgical specialties.

6Cohera Medical
TypeDirect peer
Description

Specialty developer of resorbable surgical adhesives (Sylys, TissuGlu) for plastic, abdominal, and general surgery. Closely comparable as a focused biosurgical adhesive developer in a similar regulatory and clinical stage.

7Arch Therapeutics
TypeDirect peer
Description

Developer of self-assembling peptide-based hemostatic and sealant products (AC5). Comparable as a small-cap, clinically focused biosurgical hemostatic/sealant developer targeting surgical tissue repair.

8Tissuemed
TypeDirect peer
Description

UK-based developer of TissuePatch surgical sealant films for dural and tissue sealing. Comparable as a focused biosurgical tissue-sealant company with overlapping product positioning in surgical tissue repair.

9Innocoll Pharmaceuticals
TypeEmerging player
Description

Specialty collagen-based surgical and wound-care product developer with biodegradable matrices. Comparable as an emerging player in collagen/biopolymer-based surgical and tissue-repair devices with overlapping biomaterials expertise.

10CorMatrix Cardiovascular
TypeEmerging player
Description

Developer of ECM-based biomaterial products for cardiac and vascular tissue repair. Comparable as a niche biosurgical tissue-repair company focused on absorbable biomaterial scaffolds in surgical applications.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LifeBond

Surgical Medical Deviceslife-bond.com

LifeBond is an Israel-based medical device company developing and manufacturing biosurgical products for tissue repair. Founded in 2007 in Caesarea and backed by Israeli and Asian life-sciences investors, it operates as a small private venture-backed biomaterials specialist.

What LifeBond does

LifeBond is a privately held medical device company founded in 2007 and headquartered in Caesarea, Israel. The company develops and manufactures biosurgical medical devices for tissue repair, operating in the regulated biomaterials segment of the surgical device market. LifeBond was incubated by Trendlines Group in 2007 and has since raised approximately $56.5 million across multiple venture rounds through August 2015, with investors including Pitango VC, Giza Venture Capital, GlenRock Israel, The Zitelman Group, BizTEC, Aurum Ventures MKI, and the strategic investor Sino Biopharmaceutical.

The company's product portfolio and underlying technology are not detailed in the source data, but its positioning as a biosurgical tissue-repair specialist implies proprietary biomaterial formulations, likely with associated patents and regulatory pathways (FDA / CE Mark) typical of the category. Founder Ishay Attar remains associated with the company, indicating continuity of technical leadership. The current organization is small, with 1–10 employees reported in the firmographic record.

LifeBond's business model is consistent with a clinical-stage or early-commercial medical device company: revenue is generated (or intended to be generated) through sales of regulated surgical products to hospitals and surgical centers, typically via specialty distributors. However, the source data does not disclose pricing, customer counts, distribution arrangements, or revenue figures, and no commercial sales milestones, product launches, or partnership announcements are documented beyond the venture financings. As a result, the company's current commercial stage cannot be confirmed from available information.

LifeBond firmographics

Firmographics
Name
LifeBond
Website
https://life-bond.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
LifeBond is an Israel-based medical device company developing and manufacturing biosurgical products for tissue repair. Founded in 2007 in Caesarea and backed by Israeli and Asian life-sciences investors, it operates as a small private venture-backed biomaterials specialist.
Ownership category
akta.pro rank

LifeBond industry classification

Industry
Product category
Surgical Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Adhesives & Sealants (2891)
akta.pro primary industry
Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)
akta.pro secondary industry
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

  • Biosurgical medical devices
  • Tissue repair products
  • Surgical hemostats
  • Sealant medical devices
  • Biomaterial implants

Where LifeBond is headquartered

Location

Headquarters

HQ city
Caesarea
HQ country
Israel
HQ region
Middle East

Markets served

LifeBond business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

LifeBond product offering

Product offering

Core offering

LifeBond develops and manufactures biosurgical medical devices intended for tissue repair applications. The company produces surgical sealants, hemostats, and other biomaterial-based products that surgeons use to control bleeding, seal tissues, and support healing during surgical procedures.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biosurgical Tissue Repair Devices

Companies that use LifeBond

Customer profile

Ideal customer profiles1 record

LifeBond technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LifeBond partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

LifeBond competitors and assessment

Company assessment

Direct peers

  • Artivion (formerly CryoLife): Specialized surgical adhesives and sealants (BioGlue, BioFoam) used in cardiac and vascular surgery. Directly comparable as a focused biosurgical tissue-repair and sealant company with overlapping clinical use cases.
  • HyperBranch Medical Technology (Stryker): Developer of Adherus surgical sealants, now part of Stryker. Comparable as a specialty biosurgical sealant developer focused on dural sealing and similar neurosurgical / ENT applications with overlapping technology profile.
  • Cohera Medical: Specialty developer of resorbable surgical adhesives (Sylys, TissuGlu) for plastic, abdominal, and general surgery. Closely comparable as a focused biosurgical adhesive developer in a similar regulatory and clinical stage.
  • Arch Therapeutics: Developer of self-assembling peptide-based hemostatic and sealant products (AC5). Comparable as a small-cap, clinically focused biosurgical hemostatic/sealant developer targeting surgical tissue repair.
  • Tissuemed: UK-based developer of TissuePatch surgical sealant films for dural and tissue sealing. Comparable as a focused biosurgical tissue-sealant company with overlapping product positioning in surgical tissue repair.

Broad incumbents

  • Ethicon (Johnson & Johnson MedTech): J&J's surgical solutions arm and a global incumbent in wound closure and biosurgical adjuncts (Evicel, Omnex). Comparable as a dominant surgical sealants manufacturer with deep hospital relationships and broad portfolio reach.
  • Baxter International: Diversified medical products leader whose surgical sealants and hemostats (Tisseel, Floseal) are the global category standard. Directly comparable as a manufacturer of fibrin- and gelatin-based biosurgical tissue-repair products sold into the same surgical specialties.

Others

  • B. Braun: Global medical device and pharmaceutical company offering Histoacryl tissue adhesives and broader surgical sealants portfolio. Comparable as a manufacturer of cyanoacrylate-based and other surgical tissue-repair products distributed globally.

Emerging players

  • Innocoll Pharmaceuticals: Specialty collagen-based surgical and wound-care product developer with biodegradable matrices. Comparable as an emerging player in collagen/biopolymer-based surgical and tissue-repair devices with overlapping biomaterials expertise.
  • CorMatrix Cardiovascular: Developer of ECM-based biomaterial products for cardiac and vascular tissue repair. Comparable as a niche biosurgical tissue-repair company focused on absorbable biomaterial scaffolds in surgical applications.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

LifeBond social profiles

Digital presence

LifeBond financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LifeBond leadership team

Management profile

Number of profiles

Profiles1 record

LifeBond funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LifeBond M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeBond

What does LifeBond do?

LifeBond develops and manufactures biosurgical medical devices intended for tissue repair applications. The company produces surgical sealants, hemostats, and other biomaterial-based products that surgeons use to control bleeding, seal tissues, and support healing during surgical procedures.

When was LifeBond founded?

LifeBond was founded in 2007. It employs 1 to 10 people.

Where is LifeBond based?

LifeBond is headquartered in Caesarea, Israel, in the Middle East region.

Who are LifeBond's main competitors?

Direct peers on record are Artivion (formerly CryoLife), HyperBranch Medical Technology (Stryker), Cohera Medical, Arch Therapeutics and Tissuemed. Broad incumbents are Ethicon (Johnson & Johnson MedTech) and Baxter International. B. Braun is listed as an others. Emerging players are Innocoll Pharmaceuticals and CorMatrix Cardiovascular.

Does LifeBond have an API?

No public API is recorded for LifeBond.

What industry is LifeBond in?

LifeBond's product category is Surgical Medical Devices. Its primary akta.pro industry code is IMAEAOAL, Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLifeBond's Multi-Center International Pivotal Study of the LifeSeal Surgical Sealant for GI Resections is Enrolling Patients in the US and EuropeLifeBond announced that 20 leading medical centers in the United States and Western Europe are now recruiting patients for the company's international pivotal study of LifeSeal Surgical Sealant, with an additional 20 US clinical sites expected to follow. The randomized IDE clinical trial compares patients undergoing colorectal anastomosis with and without LifeSeal, which is designed to provide reinforcement and minimize staple-line leakage. LifeBond received FDA permission to commence the study under the Expedited Access Pathway program and achieved CE Marking in April 2016, enabling commercial use of LifeSeal in several Western European countries.PR NewswireLifeBond Wins Frost & Sullivan 2016 European New Product Innovation AwardLifeBond has been awarded the 2016 European New Product Innovation Award by Frost & Sullivan for its LifeSeal® Surgical Sealant, a device designed to reduce staple-line leakage in gastrointestinal surgeries. This recognition follows recent regulatory milestones, including FDA Investigational Device Exemption approval and CE marking in Europe. The company intends to leverage this momentum to advance clinical development and commercialization of its bio-surgical medical devices.PR NewswireLifeBond Receives FDA IDE Approval for LifeSeal GI Surgical Sealant Clinical TrialLifeBond announced FDA IDE approval to initiate a multicenter, multinational clinical trial for its LifeSeal Surgical Sealant Kit, designed to prevent staple-line leakage in gastrointestinal resection procedures. The randomized, double-arm study will enroll patients at clinical sites in Europe with additional US sites to follow, building on prior EU clinical data showing leakage reduction and the product's existing CE marking. The approval marks a key milestone toward US commercialization, with the FDA's Expedited Access Pathway designation already highlighting the product's medical significance.PR NewswireGlobal Medical Adhesives and Sealant IndustryThis July 2016 industry report analyzes the global medical adhesives and sealants market from 2015 through 2022, covering product segments including synthetic adhesives (acrylic, cyanoacrylate, silicone) and natural adhesives (albumin, collagen, fibrin), with applications in dental and medical fields. The report provides market data and forecasts for eight geographic regions, identifies key industry drivers such as aging populations and increasing surgical procedures, and profiles 63 companies operating in this sector. Notable corporate activities documented include Cohera Medical's FDA approval for TissuGlu and $50 million funding round, LifeBond's $27 million funding, and several acquisitions including Integra LifeSciences' purchase of the DuraSeal product series and DENTSPLY's merger with Sirona Dental Systems.PR NewswireLifeBond Secures CE Marking for LifeSeal™ Surgical Sealant for GI ProceduresIsraeli medical device company LifeBond has received CE Marking approval for its LifeSeal™ Surgical Sealant, a gastrointestinal sealant designed to minimize staple-line leakage during GI resection procedures, enabling commercial sale across 32 European countries with a combined population of nearly 500 million. The company also announced that its product received FDA's Expedited Access Pathway designation and priority processing status, with plans to launch in select European markets within the next year and commence a new international pivotal study including US and European sites. Anastomotic leakage occurs in 15-19% of colorectal resection patients, and LifeBond claims LifeSeal has the potential to improve patient outcomes while reducing healthcare costs associated with post-surgical complications.FinSMEsLifeBond Closes $20M Series C Financing RoundLifeBond, an Israeli biosurgery device company, closed a $20M Series C round led by Giza Venture Capital and Aurum Ventures. The funds will advance pre-clinical and clinical development of its LifeSealGI sealant, targeting market entry by end of 2012 pending regulatory approval.